The content on this site is intended for healthcare professionals only
Dr Jason Luke talks to ecancer for the ESMO 2021 meeting about the overall survival results from the phase III KEYNOTE-716 study.
This study looked at the use of pembrolizumab versus placebo after complete resection of high-risk stage II melanoma.
Dr Luke explains that this was an international randomised placebo-controlled double-blind study where patients were split 1-1 between pembrolizumab and placebo.
He reports that patients who received pembrolizumab experienced a 35% reduction in the risk of recurrence and also the number of distant metastasis recurrences.
Read more about this study here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Use of bispecifics and CAR T cells in South America
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Latest in EGFR mutated NSCLC
3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157 plus pembrolizumab in resected melanoma
PD-1–refractory advanced melanoma: how do we get to the finish line?
